Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Return on Sales (2024 - 2025)

Zentalis Pharmaceuticals has reported Return on Sales over the past 2 years, most recently at 5.56% for Q3 2025.

  • Quarterly results put Return on Sales at 5.56% for Q3 2025, down 114.0% from a year ago — trailing twelve months through Sep 2025 was 5.56% (down 114.0% YoY), and the annual figure for FY2024 was 2.46%, changed.
  • Return on Sales for Q3 2025 was 5.56% at Zentalis Pharmaceuticals, up from 6.06% in the prior quarter.
  • Over the last five years, Return on Sales for ZNTL hit a ceiling of 0.25% in Q1 2024 and a floor of 8.34% in Q1 2025.